OncoMatch/Clinical Trials/NCT04901936

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Is NCT04901936 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pegcetacoplan for paroxysmal nocturnal hemoglobinuria (pnh).

Phase 2RecruitingApellis Pharmaceuticals, Inc.NCT04901936Data as of May 2026

Treatment: Pegcetacoplan — The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).

Check if I qualify

Extracted eligibility criteria

Lab requirements

Blood counts

platelet count >75,000/mm3 and absolute neutrophil count >1000/mm3

Have a platelet count >75,000/mm3 and an absolute neutrophil count >1000/mm3

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Children's Hospital of Atlanta · Atlanta, Georgia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify